CD82 Protein, Human, Recombinant (His)

カタログ番号 TMPY-02030

別名: CD82 molecule, SAR2, R2, KAI-1, 4F9, KAI1, C33, TSPAN27, ST6, IA4, GR15

CD82, also known as KAI-1, structurally belongs to tetraspanin family while categorised as metastasis suppressor gene on functional grounds. KAI1/CD82 is localized on cell membrane and form interactions with other tetraspanins, integrins and chemokines which are respectively responsible for cell migration, adhesion and signalling. Downregulation of CD82 expression is associated with the advanced stages of many human cancers and correlates with the acquisition of metastatic potential. Recent studies suggest that complex mechanisms underlie CD82 loss of function, including altered transcriptional regulation, splice variant production and post-translational protein modifications, and indicate a central role for CD82 in controlling metastasis as a 'molecular facilitator'. The loss of KAI1/CD82 expression in invasive and metastatic cancers is due to a complex, epigenetic mechanism that probably involves transcription factors such as NFkappaB, p53, and beta-catenin. A loss of KAI1 expression is also associated with the advanced stages of many human malignancies and results in the acquisition of invasive and metastatic capabilities by tumour cells. Thus, KAI1/CD82 is regarded as a wide-spectrum tumor metastasis suppressor.

All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.

CD82 Protein, Human, Recombinant (His)

パッケージサイズ	在庫状況	単価(税別)
50 μg	在庫あり	￥ 73,500
100 μg	約5 days	￥ 130,500
200 μg	約5 days	￥ 229,500
500 μg	約5 days	￥ 486,500

バルクのお問い合わせ

バッチを選択

COA DATASHEET SDS

生物学的特性に関する説明

Technical Params

Product Properties

参考文献

生物学的情報

Testing in progress

説明

Species	Human
Expression Host	HEK293
Tag	His
Accession Number	P27701-1
別名	CD82 molecule, SAR2, R2, KAI-1, 4F9, KAI1, C33, TSPAN27, ST6, IA4, GR15
Construction	A DNA sequence encoding the second extracellular domain of human CD82 (P27701-1) (Gly 111-Leu 228) was fused with a polyhistidine tag at the C-terminus and a signal peptide at the N-terminus.
Protein Purity	> 90 % as determined by SDS-PAGE
分子量	15 kDa (predicted)

Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method.
Formulation	Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0. 01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
Reconstitution	A hardcopy of datasheet with reconstitution instructions is sent along with the products. Please refer to it for detailed information.
Stability & Storage	Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	CD82, also known as KAI-1, structurally belongs to tetraspanin family while categorised as metastasis suppressor gene on functional grounds. KAI1/CD82 is localized on cell membrane and form interactions with other tetraspanins, integrins and chemokines which are respectively responsible for cell migration, adhesion and signalling. Downregulation of CD82 expression is associated with the advanced stages of many human cancers and correlates with the acquisition of metastatic potential. Recent studies suggest that complex mechanisms underlie CD82 loss of function, including altered transcriptional regulation, splice variant production and post-translational protein modifications, and indicate a central role for CD82 in controlling metastasis as a 'molecular facilitator'. The loss of KAI1/CD82 expression in invasive and metastatic cancers is due to a complex, epigenetic mechanism that probably involves transcription factors such as NFkappaB, p53, and beta-catenin. A loss of KAI1 expression is also associated with the advanced stages of many human malignancies and results in the acquisition of invasive and metastatic capabilities by tumour cells. Thus, KAI1/CD82 is regarded as a wide-spectrum tumor metastasis suppressor.

参考文献

1. Malik FA,et al.(2009) KAI-1/CD82, the molecule and clinical implication in cancer and cancer metastasis. Histol Histopathol. 24(4): 519-30. 2. Liu WM,et al.(2006) KAI1/CD82, a tumor metastasis suppressor. Cancer Lett. 240(2): 183-94. 3. Tonoli H,et al.(2006) CD82 metastasis suppressor gene: a potential target for new therapeutics? Trends Mol Med. 11(12): 563-70. 4. Jackson P,et al.(2005) KAI1 tetraspanin and metastasis suppressor. Int J Biochem Cell Biol. 37(3): 530-4.

Calculator

Reconstitution Calculator

Recombinant Proteins Dilute Calculator

Specific Activity Calculator

bottom

技術サポート

Please read the User Guide of Recombinant Proteins for more specific information.

Keywords

CD82 Protein, Human, Recombinant (His) R-2 IA 4 SAR-2 IA-4 SAR 2 TSPAN 27 ST 6 TSPAN-27 GR-15 CD82 molecule SAR2 R2 KAI-1 GR 15 4F9 KAI1 KAI 1 C-33 C33 ST-6 C 33 TSPAN27 ST6 R 2 IA4 GR15 recombinant recombinant-proteins proteins protein